<DOC>
	<DOCNO>NCT00112879</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Thalidomide may stop growth multiple myeloma block blood flow cancer . Giving arsenic trioxide together ascorbic acid , dexamethasone , thalidomide may kill cancer cell . PURPOSE : This phase II trial study well give arsenic trioxide together ascorbic acid , dexamethasone , thalidomide work treat patient multiple myeloma .</brief_summary>
	<brief_title>Arsenic Trioxide , Ascorbic Acid , Dexamethasone , Thalidomide Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient previously untreated high-risk relapsed refractory multiple myeloma ( MM ) treat arsenic trioxide , ascorbic acid , dexamethasone , thalidomide . - Determine safety regimen patient . Secondary - Determine duration response , progression-free survival , overall survival patient previously untreated high-risk MM treat regimen . OUTLINE : This open-label study . - Induction therapy : Patients receive arsenic trioxide IV 1-4 hour ascorbic acid IV 15-30 minute day 1-5 week 1 twice weekly week 2-12 ; oral dexamethasone day 1-4 , 11-14 , 29-32 , 39-42 , 57-60 , 67-70 ( week 1 , 2 , 5 , 6 , 9 , 10 ) ; oral thalidomide daily week 1-12 . - Consolidation therapy : Beginning 4 week completion induction therapy , patient receive arsenic trioxide ascorbic acid induction therapy ; oral dexamethasone day 1-4 , 29-32 , 57-60 ( week 1 , 5 , 9 ) ; oral thalidomide daily week 1-12 . - Maintenance therapy : Beginning 4 week completion consolidation therapy , patient receive arsenic trioxide IV 1-4 hour ascorbic acid IV 15-30 minute day 1 , 8 , 15 , 22 . Treatment arsenic trioxide ascorbic acid repeat every 90 day ( every 12 week ) . Patients also receive oral dexamethasone day 1-4 . Treatment dexamethasone repeat every 28 day . Patients receive oral thalidomide daily . Maintenance therapy continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week every 6 month thereafter . PROJECTED ACCRUAL : A total 33-68 patient ( 15-34 previously untreated high-risk multiple myeloma [ MM ] 18-34 relapse refractory MM ) accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma ( MM ) , meet 1 follow criterion : Previously untreated disease poor prognosis , meet 1 follow criterion : Active disease β2 microglobulin ≥ 5.5 mg/dL Inactive disease peripheral plasma cell OR chromosome 13 14 abnormality fluorescent situ hybridization Relapsed refractory disease Measurable disease serum urine Mprotein and/or measurable plasmacytoma PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02* NOTE : *ECOG 3 allow patient bone pain due MM Life expectancy At least 3 month Hematopoietic Platelet count ≥ 75,000/mm^3 unless plasma cell &gt; 50 % bone marrow Any WBC allow provide plasma cell &gt; 50 % bone marrow Hepatic SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Renal Creatinine ≤ 6.0 mg/dL Cardiovascular Absolute QT interval ≤ 460 msec potassium ≥ 4.0 mEq/L AND magnesium ≥ 1.8 mg/dL No conduction defect No unstable angina No myocardial infarction within past 6 month No congestive heart failure No New York Heart Association class IIIV heart disease No significant underlying cardiac dysfunction Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception ≥ 4 week , , ≥ 4 week completion study therapy No blood , ovum , sperm donation study participation No history grand mal seizure except infantile febrile seizures No preexist neurotoxicity neuropathy ≥ grade 2 No uncontrolled diabetes mellitus No active serious infection control antibiotic No malignancy within past 5 year except curatively treat carcinoma situ cervix nonmelanoma skin cancer No condition would preclude study compliance follow PRIOR CONCURRENT THERAPY : Biologic therapy Prior thalidomide allow ( patient relapse refractory MM ) No prior thalidomide combination arsenic trioxide Prior epoetin alfa allow Chemotherapy See Biologic therapy Prior arsenic trioxide allow ( patient relapse refractory MM ) No concurrent cytotoxic chemotherapy No chemotherapy within 2 week completion study treatment Endocrine therapy Prior steroid therapy allow ( patient relapse refractory MM ) Radiotherapy No concurrent broadfield radiotherapy Surgery Not specify Other Prior concurrent bisphosphonates allow No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>